Investors like Abbvie stock for a number of reasons.
Eli Lilly remains the highest stock to buy and hold.
Vertex Pharmaceuticals is growing rapidly to expand its market beyond cystic fibrosis.
Our 10 Better Stocks than Abbvie›
The “IT” factor. Some stocks have. Other stocks don’t. But those are indeed unstoppable.
Three Motley Fool contributors believe they have found unstoppable stocks that bought in August with the “IT” factor — all in the healthcare sector. That’s why they choose Abbvie(NYSE: ABBV),,,,, Yililai(NYSE: LLY)and Pinpoint Drugs(NASDAQ: VRTX).
Image source: Getty Images.
Prosper Junior Bakiny (Abbvie): It has been more than two years since Abbvie lost patent exclusivity due to its best-selling drug, autoimmune disease medicine Humira. However, this did not stop Abbvie. It just slowed down temporarily. The company rebounded well and has since recovered first-class growth. Abbvie now has another sales therapy for Skyrizi, the world’s top ten sales therapies, targeting multiple immunologic conditions.
Skyrizi’s sales have been growing at an extremely fast pace. Abbvie’s immunology series, together with Rinvoq, successfully filled the gap left by Humira. This is an important reason to consider stocks: Abbvie’s ability to overcome important patent cliffs expresses a large number of roles about its ability to innovate. Apart from that, Abbvie’s lineup is very deep. It has older products that continue to make meaningful contributions to its financial performance, such as its Botox franchise and new products that can help drive growth over time, such as migraine treatment Qulipta.
Abbvie’s pipes also look very deep. The company should be able to record consistent clinical and regulatory wins.
Finally, we can’t mention Abbvie without pointing out its incredible dividend record. The company is part of the Exclusive Dividend Kings Group, with its positive continuous increase in 53 consecutive payments, including its time as a division of the former parent company Abbott Laboratory. Abbvie’s forward rate of return is much higher than S&P 500On average, it has a cash payment ratio of 61.8%.
Apart from a great base business, a strong lineup and a solid pipeline, Abbvie is an outstanding stock for investors seeking income. Investments in the company may yield higher returns in the long run.
David Jagielski(Eli Lilly): The stock that looks unstoppable now is Eli Lilly. While many investors will focus on their very successful GLP-1 drug, Zepbough and Mounjaro are the main reasons for investing in the business, there are more reasons behind the company and why it is the highest growth stock.
Eli Lilly has a promising Alzheimer’s treatment, Kisunla, which was approved by regulators last year. It is still in the early stages of growth, with annual revenues of up to $5 billion, according to analysts. Meanwhile, Eli Lilly is still focusing on developing more life-changing treatments for patients. It plans to invest $4.5 billion in research and manufacturing plants, calling it the Eli Lilly Medical Foundry. By leveraging new manufacturing methods to ensure high efficiency, new centers can help companies scale and bring new products to market faster.
The company also has a wealth of resources to help it invest in R&D and may gain promising businesses in the process. In the 12-month period, Eli Lilly made $11.1 billion in sales, totaling $49 billion. The company’s outstanding profit margins, strong growth prospects, and commitment to producing new therapies are why this drug can be one of the best investments you can invest in your portfolio right now.
Keith Speights (Vertex Pharmaceuticals): To be truly unstoppable, a company cannot compete, which can stop it. Vertex Pharmaceuticals covers the cystic fibrosis (CF) series. No other pharmaceuticals have approved treatments for the root cause of CF. The number of companies using experimental CF therapy in advanced clinical testing may compete with the total number of apex…zero.
In fact, Vertex’s biggest competitor in treating CF is itself. The company’s latest CF therapy, Alyftrek, offers a more convenient one-dose than current top ticket seller Kaftrio/Trikafta. However, CF is not the main reason why I like vertices. My main interest is in other signs of biotech innovators.
For example, Vertex won regulatory approval from Journavx earlier this year. This is the first new type of painkiller in more than 20 years. Journavx is safe and effective, with no opioid-related side effects and addictive potential – because it is not an opioid.
The company’s pipeline has promising late-stage plans that can further expand the market opportunities of the pinnacle. Inaxaplin targets APOL1-mediated renal disease, which affects approximately 250,000 patients worldwide. Povetacicept has the potential to treat a variety of kidney diseases, with IGA nephropathy first appearing on the list, with more than 1 million patients. Zimislecel can cure severe type 1 diabetes.
At first glance, Vertex seems to be premium, with its stock trading at 26.3 times. However, the company’s growth prospects are so strong that its valuation is attractive. Based on analysts’ five-year earnings growth estimates, Vertex’s real earnings growth rate (PEG) ratio is an ultra-low 0.58.
Before you buy stocks at Abbvie, consider the following:
this Motley Fool Stock Advisor The analyst team just confirmed what they think is 10 Best Stocks For investors, buying now…Abbvie is not one of them. Ten stocks with layoffs could generate monster returns in the coming years.
When to consider Netflix On this list on December 17, 2004…If you invested $1,000 when you suggested, You will have $625,254! *Or when Nvidia This list was listed on April 15, 2005…If you invested $1,000 when you suggested, You will have $1,090,257! *
Now, it’s worth noting Stock Consultant Total average return is 1,036% – The performance on the market is better than the performance of the 500 S&P 500 index. Stock Consultant.
View 10 stocks »
*Stock Advisor Returns as of July 29, 2025
David Jagielski has no position in any of the stocks mentioned. Keith Speights has positions in Abbvie and Vertex Pharmaceuticals. Prosper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. Motley Fool has a place and recommends Abbvie, Abbott Laboratories and Vertex Pharmaceuticals. Motley Fool has a disclosure policy.
August was originally published by Motley Fool 3 unstoppable stocks
